2. Protein Tyrosine Kinase/RTK
  3. Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R
  4. Ceritinib

Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.

For research use only. We do not sell to patients.

CAS No. : 1032900-25-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg In-stock
1 g In-stock
2 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 40 publication(s) in Google Scholar

Other Forms of Ceritinib:

Ceritinib Related Antibodies

Top Publications Citing Use of Products

40 Publications Citing Use of MCE Ceritinib

Cell Imaging/Staining
In Vivo Efficacy Study
WB
Cell Proliferation/Viability Assay

    Ceritinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Apr 23;15(1):3422.  [Abstract]

    At 48 h following transfection, the cells were treated with increasing concentrations of ceritinib for 72 h.

    Ceritinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227.  [Abstract]

    Oral olaparib (50 mg/kg) and ceritinib (7.5 mg/kg), either alone or in combination, five times per week, Tumor volume and Kaplan–Meier survival curves of mice bearing subcutaneous injected SKOV3 ovarian tumors.

    Ceritinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227.  [Abstract]

    Western blot analysis of indicated proteins in PARPi-sensitive triple-negative breast cancer (TNBC) cells (parental) and TNBC cells with acquired resistance to PARPi (#6 and #15) treated with 50 nM PARPi (talazoparib) or 0.5 µM ALK inhibitor (ALKi; ceritinib), either alone or in combination, for 48 hours.

    Ceritinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227.  [Abstract]

    Representative images of clonogenic assay results in PARPiresistant ovarian and TNBC cells in the presence of the indicated inhibitor for 12 days. Synergistic inhibition of cell proliferation is defined as CI < 1. CER, ceritinib; OLA, olaparib; Comb, combination of ceritinib and olaparib.

    Ceritinib purchased from MedChemExpress. Usage Cited in: Cell Discov. 2021 May 11;7(1):33.  [Abstract]

    BEAS-2B cells were transfected with GFP–EML4–ALK for 24 h. Cells were treated with DMSO or ALK inhibitors, alectinib (500 nM), ceritinib (500 nM), and GFP fluorescence was monitored through live imaging for up to 12 h.

    Ceritinib purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2017 Aug;11(8):996-1006.  [Abstract]

    Dose-response and time course comparison of ALK inhibition by Crizotinib or Ceritinib.

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency[1][2].

    IC50 & Target

    IC50: 0.2 nM (ALK), 7 nM (InsR), 8 nM (IGF-1R), 23 nM (STK22D), 60 nM (FLT3), 260 nM (FGFR2)[1]
    Cellular Effect
    Cell Line Type Value Description References
    786-0 IC50
    2.7 3
    Compound: LDK378
    Antiproliferative activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    786-0 IC50
    2.7 3
    Compound: LDK378
    Antiproliferative activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    786-0 IC50
    2.7 3
    Compound: LDK378
    Antiproliferative activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    A-375 IC50
    1.043 3
    Compound: LDK378
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    A-375 IC50
    1.043 3
    Compound: LDK378
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    A-375 IC50
    1.043 3
    Compound: LDK378
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    A549 IC50
    1.2 3
    Compound: 2
    Antiproliferative activity against ALK-negative human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against ALK-negative human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    A549 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30223120]
    A549 GI50
    845 1
    Compound: 1
    Cytotoxicity against ALK-negative human A549 cells harboring wild type PI3KCA and CDKN2A and KRAS mutations assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against ALK-negative human A549 cells harboring wild type PI3KCA and CDKN2A and KRAS mutations assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32184963]
    A549 IC50
    2.72 3
    Compound: Ceritinib
    Antiproliferative activity against EGFR positive human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EGFR positive human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    A549 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells harboring EGFR after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells harboring EGFR after 72 hrs by MTT assay
    		[PMID: 29174809]
    A549 IC50
    0.081 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    A549 IC50
    >10 3
    Compound: Ceritinib
    Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    A549 IC50
    0.51 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells harbouring EGFR G1202R mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells harbouring EGFR G1202R mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    A549 IC50
    2.77 3
    Compound: LDK378
    Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    A549 IC50
    >1 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30223120]
    A549 IC50
    1.2 3
    Compound: 2
    Antiproliferative activity against ALK-negative human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against ALK-negative human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hr by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hr by MTT assay
    		[PMID: 33069079]
    A549 IC50
    1.32 3
    Compound: LDK378
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    A549 IC50
    2.16 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    A549 IC50
    > 10 3
    Compound: LDK378
    Cytotoxicity against EGFR-positive human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against EGFR-positive human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    A549 IC50
    1.43 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    A549 IC50
    1.61 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    A549 IC50
    >10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    A549 IC50
    1.61 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 36113668]
    A549 IC50
    1.61 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    A549 IC50
    0.081 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    A549 IC50
    2.142 3
    Compound: LDK378
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    A549 IC50
    >10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hr by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hr by MTT assay
    		[PMID: 33069079]
    A549 IC50
    2.142 3
    Compound: LDK378
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    A549 IC50
    0.51 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells harbouring EGFR G1202R mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells harbouring EGFR G1202R mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    A549 IC50
    1.43 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    A549 IC50
    2.16 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    A549 IC50
    1.2 3
    Compound: 2
    Antiproliferative activity against ALK-negative human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against ALK-negative human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    A549 IC50
    2.72 3
    Compound: Ceritinib
    Antiproliferative activity against EGFR positive human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EGFR positive human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    A549 IC50
    1.32 3
    Compound: LDK378
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    A549 IC50
    1.32 3
    Compound: LDK378
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    A549 IC50
    >10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 36113668]
    A549 IC50
    2.77 3
    Compound: LDK378
    Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    A549 IC50
    1.43 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    A549 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells harboring EGFR after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells harboring EGFR after 72 hrs by MTT assay
    		[PMID: 29174809]
    A549 IC50
    1.61 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    A549 IC50
    >1 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells harboring EGFR after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells harboring EGFR after 72 hrs by MTT assay
    		[PMID: 29174809]
    A549 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30223120]
    A549 IC50
    1.61 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    A549 IC50
    0.51 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells harbouring EGFR G1202R mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells harbouring EGFR G1202R mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    A549 IC50
    >10 3
    Compound: LDK378
    Cytotoxicity against EGFR-positive human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against EGFR-positive human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    A549 IC50
    2.142 3
    Compound: LDK378
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hr by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hr by MTT assay
    		[PMID: 33069079]
    A549 IC50
    >10 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    A549 IC50
    2.16 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    A549 IC50
    2.72 3
    Compound: Ceritinib
    Antiproliferative activity against EGFR positive human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EGFR positive human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    A549 IC50
    0.081 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    A549 IC50
    1.61 3
    Compound: Ceritinib
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    A549 IC50
    2.77 3
    Compound: LDK378
    Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    AGS IC50
    2.24 3
    Compound: LDK378
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    A549 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 36113668]
    A549 GI50
    845 1
    Compound: 1
    Cytotoxicity against ALK-negative human A549 cells harboring wild type PI3KCA and CDKN2A and KRAS mutations assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against ALK-negative human A549 cells harboring wild type PI3KCA and CDKN2A and KRAS mutations assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32184963]
    BaF3 EC50
    >5 3
    Compound: Ceritinib
    Antiproliferative activity against mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Antiproliferative activity against mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    A549 IC50
    > 10 3
    Compound: LDK378
    Cytotoxicity against EGFR-positive human A549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against EGFR-positive human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    AGS IC50
    2.24 3
    Compound: LDK378
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    AGS IC50
    2.24 3
    Compound: LDK378
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    BaF3 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity IL3 dependent human Ba/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity IL3 dependent human Ba/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 EC50
    3 3
    Compound: Ceritinib
    Inhibition of EGFR L858R mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR L858R mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 EC50
    >3 3
    Compound: Ceritinib
    Inhibition of wild type EGFR (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of wild type EGFR (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 CC50
    75 1
    Compound: LDK378
    Antiproliferative activity against mouse BAF3 cells expressing ALK L1196M mutant
    Antiproliferative activity against mouse BAF3 cells expressing ALK L1196M mutant
    		[PMID: 26235945]
    BaF3 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity against mouse BAF3 cells harboring G1202R mutation after 72 hrs by MTT assay
    Antiproliferative activity against mouse BAF3 cells harboring G1202R mutation after 72 hrs by MTT assay
    		[PMID: 30223120]
    BaF3 IC50
    >1 3
    Compound: 3
    Antiproliferative activity against IL3-stimulated mouse BAF3 cells after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against IL3-stimulated mouse BAF3 cells after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    BaF3 CC50
    75 1
    Compound: LDK378
    Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay
    Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay
    		[PMID: 26923695]
    BaF3 IC50
    > 1000 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 G2032R mutant after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 G2032R mutant after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    BaF3 IC50
    > 1000 1
    Compound: 3
    Antiproliferative activity against IL3-stimulated mouse BAF3 cells after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against IL3-stimulated mouse BAF3 cells after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    BaF3 IC50
    >1 3
    Compound: Ceritinib
    Antiproliferative activity against mouse BAF3 cells harboring G1202R mutation after 72 hrs by MTT assay
    Antiproliferative activity against mouse BAF3 cells harboring G1202R mutation after 72 hrs by MTT assay
    		[PMID: 30223120]
    BaF3 EC50
    2500 1
    Compound: Ceritinib
    Inhibition of EGFR T790M/L858R double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR T790M/L858R double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 EC50
    > 3000 1
    Compound: Ceritinib
    Inhibition of wild type EGFR (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of wild type EGFR (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    >1 3
    Compound: Ceritinib
    Antiproliferative activity IL3 dependent human Ba/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity IL3 dependent human Ba/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 EC50
    2500 1
    Compound: Ceritinib
    Inhibition of EGFR exon19 deletion mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR exon19 deletion mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    > 5 3
    Compound: Ceritinib
    Cytotoxicity against mouse BA/F3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BA/F3 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    BaF3 IC50
    1.01 3
    Compound: Ceritinib
    Cytotoxicity against mouse BA/F3 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BA/F3 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    BaF3 EC50
    26 1
    Compound: Ceritinib
    Inhibition of EML4/ALK (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EML4/ALK (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    >5 3
    Compound: Ceritinib
    Cytotoxicity against mouse BA/F3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BA/F3 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    BaF3 EC50
    > 5000 1
    Compound: Ceritinib
    Antiproliferative activity against mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Antiproliferative activity against mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 EC50
    2660 1
    Compound: Ceritinib
    Inhibition of EGFR T790M exon19 deletion double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR T790M exon19 deletion double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    1.01 3
    Compound: Ceritinib
    Cytotoxicity against mouse BA/F3 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BA/F3 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    BaF3 IC50
    >2 3
    Compound: 6, LDK378
    Cytotoxicity against wild type mouse BA/F3 cells assessed as growth inhibition
    Cytotoxicity against wild type mouse BA/F3 cells assessed as growth inhibition
    		[PMID: 23837797]
    BaF3 EC50
    3000 1
    Compound: Ceritinib
    Inhibition of EGFR L858R mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR L858R mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    10.7 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    SR IC50
    2.2 1
    Compound: Ceritinib
    Antiproliferative activity against ALK positive human SR cells
    Antiproliferative activity against ALK positive human SR cells
    		[PMID: 33751979]
    BaF3 EC50
    > 3000 1
    Compound: Ceritinib
    Inhibition of wild type EGFR (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of wild type EGFR (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    101 1
    Compound: 2
    Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    EA.hy 926 IC50
    1.01 3
    Compound: Ceritinib
    Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    		[PMID: 37087886]
    HCC78 IC50
    0.039 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    BaF3 EC50
    > 5000 1
    Compound: Ceritinib
    Antiproliferative activity against mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Antiproliferative activity against mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    164 1
    Compound: 2
    Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    234 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    HCC78 IC50
    0.058 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    		[PMID: 29174809]
    BaF3 IC50
    1.01 3
    Compound: Ceritinib
    Cytotoxicity against mouse BA/F3 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BA/F3 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    HCC78 IC50
    0.058 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    		[PMID: 30223120]
    BaF3 IC50
    2477 1
    Compound: 2; LDK378
    Antiproliferative activity against wild type mouse BaF3 cells assessed as reduction in cell growth incubated for 2 to 3 days by Bright-Glo luciferase assay
    Antiproliferative activity against wild type mouse BaF3 cells assessed as reduction in cell growth incubated for 2 to 3 days by Bright-Glo luciferase assay
    		[PMID: 26750252]
    BaF3 IC50
    10.7 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    BaF3 IC50
    2477 1
    Compound: 15b, LDK378
    Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    HCC78 IC50
    >1 3
    Compound: 3
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    HCC78 IC50
    0.018 3
    Compound: Ceritinib
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    BaF3 IC50
    101 1
    Compound: 2
    Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 EC50
    2500 1
    Compound: Ceritinib
    Inhibition of EGFR exon19 deletion mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR exon19 deletion mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    HCC78 IC50
    0.058 3
    Compound: LDK378
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    BaF3 IC50
    164 1
    Compound: 2
    Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 EC50
    2500 1
    Compound: Ceritinib
    Inhibition of EGFR T790M/L858R double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR T790M/L858R double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    1666 1
    Compound: Ceritinib
    Cytotoxicity against mouse BaF3 cells assessed as inhibition of cell growth in presence of IL-3
    Cytotoxicity against mouse BaF3 cells assessed as inhibition of cell growth in presence of IL-3
    		[PMID: 27780853]
    BaF3 EC50
    26 1
    Compound: Ceritinib
    Inhibition of EML4/ALK (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EML4/ALK (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    HCC78 IC50
    0.067 3
    Compound: Ceritinib
    Cytotoxicity against human HCC78 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    HCT-116 IC50
    1.07 3
    Compound: 2
    Antiproliferative activity against ALK-negative human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against ALK-negative human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    BaF3 IC50
    234 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    BaF3 IC50
    26 1
    Compound: 15b, LDK378
    Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    BaF3 IC50
    2477 1
    Compound: 15b, LDK378
    Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    BaF3 EC50
    2660 1
    Compound: Ceritinib
    Inhibition of EGFR T790M exon19 deletion double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR T790M exon19 deletion double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    HCT-116 IC50
    1.82 3
    Compound: Ceritinib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 IC50
    2477 1
    Compound: 2; LDK378
    Antiproliferative activity against wild type mouse BaF3 cells assessed as reduction in cell growth incubated for 2 to 3 days by Bright-Glo luciferase assay
    Antiproliferative activity against wild type mouse BaF3 cells assessed as reduction in cell growth incubated for 2 to 3 days by Bright-Glo luciferase assay
    		[PMID: 26750252]
    BaF3 IC50
    2747 1
    Compound: 2
    Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    HCT-116 IC50
    1.93 3
    Compound: LDK378
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    BaF3 IC50
    26 1
    Compound: 15b, LDK378
    Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    BaF3 EC50
    3000 1
    Compound: Ceritinib
    Inhibition of EGFR L858R mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR L858R mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    7.11 1
    Compound: Ceritinib
    Antiproliferative activity against mouse BaF3 cells overexpressing ALK assessed as inhibition of cell proliferation measured by CCK8 assay
    Antiproliferative activity against mouse BaF3 cells overexpressing ALK assessed as inhibition of cell proliferation measured by CCK8 assay
    		[PMID: 34245852]
    BaF3 IC50
    26 1
    Compound: 6, LDK378
    Cytotoxicity against mouse BA/F3 cells expressing NPM-ALK fusion gene assessed as growth inhibition
    Cytotoxicity against mouse BA/F3 cells expressing NPM-ALK fusion gene assessed as growth inhibition
    		[PMID: 23837797]
    BaF3 IC50
    319.5 1
    Compound: 15b, LDK378
    Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    BaF3 IC50
    10.7 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    HEK-293T IC50
    >10 3
    Compound: Ceritinib
    Antiproliferative activity against human HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 IC50
    2747 1
    Compound: 2
    Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    33 1
    Compound: 2
    Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    319.5 1
    Compound: 15b, LDK378
    Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    BaF3 IC50
    41 1
    Compound: 2
    Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    NCI-H2228 IC50
    15 1
    Compound: 2
    Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay
    Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay
    		[PMID: 29627725]
    BaF3 IC50
    320 1
    Compound: 6, LDK378
    Cytotoxicity against mouse BA/F3 cells transfected with Tel-InsR gene assessed as growth inhibition
    Cytotoxicity against mouse BA/F3 cells transfected with Tel-InsR gene assessed as growth inhibition
    		[PMID: 23837797]
    BaF3 IC50
    444 1
    Compound: 2
    Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    NCI-H3122 EC50
    15 1
    Compound: 2
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    SU-DHL-1 IC50
    15 1
    Compound: 2
    Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay
    Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay
    		[PMID: 29627725]
    BaF3 IC50
    33 1
    Compound: 2
    Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    54.9 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    BaF3 IC50
    40.7 1
    Compound: 6, LDK378
    Inhibition of ALK (unknown origin) transfected in mouse BA/F3 cells
    Inhibition of ALK (unknown origin) transfected in mouse BA/F3 cells
    		[PMID: 23837797]
    BaF3 IC50
    5512 1
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    HeLa IC50
    0.94 3
    Compound: LDK378
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    Hep 3B2 IC50
    2.16 3
    Compound: Ceritinib
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 IC50
    41 1
    Compound: 2
    Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    57 1
    Compound: 2
    Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    44 1
    Compound: LDK378
    Antiproliferative activity against mouse BaF3 cells harboring CD74-ROS1 assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse BaF3 cells harboring CD74-ROS1 assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 25733882]
    HEp-2 IC50
    1.83 3
    Compound: LDK378
    Antiproliferative activity against human Hep2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Hep2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    BaF3 IC50
    576.6 1
    Compound: 19
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 33243531]
    BaF3 IC50
    444 1
    Compound: 2
    Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    64 1
    Compound: 2
    Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    HepG2 IC50
    4.08 3
    Compound: Ceritinib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    BaF3 IC50
    54.9 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    BaF3 IC50
    668 1
    Compound: 2
    Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    HepG2 IC50
    0.77 3
    Compound: LDK378
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    HK-2 IC50
    2.512 3
    Compound: Ceritinib
    Cytotoxicity against human HK-2 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    Cytotoxicity against human HK-2 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    		[PMID: 37087886]
    BaF3 IC50
    5512 1
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    7.11 1
    Compound: Ceritinib
    Antiproliferative activity against mouse BaF3 cells overexpressing ALK assessed as inhibition of cell proliferation measured by CCK8 assay
    Antiproliferative activity against mouse BaF3 cells overexpressing ALK assessed as inhibition of cell proliferation measured by CCK8 assay
    		[PMID: 34245852]
    NCI-H2228 IC50
    22.1 1
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell proliferation measured by CCK8 assay
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell proliferation measured by CCK8 assay
    		[PMID: 34245852]
    BaF3 IC50
    57 1
    Compound: 2
    Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    726 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    BaF3 IC50
    576.6 1
    Compound: 19
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 33243531]
    KARPAS-299 IC50
    22.8 1
    Compound: 15b, LDK378
    Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay
    Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    BaF3 CC50
    75 1
    Compound: LDK378
    Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay
    Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay
    		[PMID: 26923695]
    BaF3 IC50
    60 1
    Compound: LDK378
    Antiproliferative activity against mouse BaF3 cells harboring CD74-ROS1 L2026M mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse BaF3 cells harboring CD74-ROS1 L2026M mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 25733882]
    BaF3 IC50
    780.5 1
    Compound: 19
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 33243531]
    KARPAS-299 IC50
    22.8 1
    Compound: 6, LDK378
    Cytotoxicity against human KARPAS299 cells expressing NPM-ALK fusion gene assessed as growth inhibition
    Cytotoxicity against human KARPAS299 cells expressing NPM-ALK fusion gene assessed as growth inhibition
    		[PMID: 23837797]
    HT-29 IC50
    1.12 3
    Compound: Ceritinib
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 IC50
    64 1
    Compound: 2
    Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    EA.hy 926 IC50
    1.01 3
    Compound: Ceritinib
    Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    		[PMID: 37087886]
    HCC78 IC50
    > 1000 1
    Compound: 3
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    HT-29 IC50
    0.7 3
    Compound: LDK378
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    BaF3 IC50
    668 1
    Compound: 2
    Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    BaF3 IC50
    7.11 1
    Compound: Ceritinib
    Antiproliferative activity against mouse BaF3 cells overexpressing ALK assessed as inhibition of cell proliferation measured by CCK8 assay
    Antiproliferative activity against mouse BaF3 cells overexpressing ALK assessed as inhibition of cell proliferation measured by CCK8 assay
    		[PMID: 34245852]
    HCC78 IC50
    0.018 3
    Compound: Ceritinib
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    HT-29 IC50
    1.03 3
    Compound: Ceritinib
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    HT-29 IC50
    >10 3
    Compound: Ceritinib
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    BaF3 IC50
    726 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    HCC78 IC50
    0.039 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    BaF3 IC50
    780.5 1
    Compound: 19
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 33243531]
    BaF3 EC50
    26 1
    Compound: Ceritinib
    Inhibition of EML4/ALK (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EML4/ALK (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    HCC78 IC50
    0.058 3
    Compound: LDK378
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    BaF3 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity against mouse BAF3 cells harboring G1202R mutation after 72 hrs by MTT assay
    Antiproliferative activity against mouse BAF3 cells harboring G1202R mutation after 72 hrs by MTT assay
    		[PMID: 30223120]
    HCC78 IC50
    0.058 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    		[PMID: 30223120]
    BaF3 IC50
    26 1
    Compound: 6, LDK378
    Cytotoxicity against mouse BA/F3 cells expressing NPM-ALK fusion gene assessed as growth inhibition
    Cytotoxicity against mouse BA/F3 cells expressing NPM-ALK fusion gene assessed as growth inhibition
    		[PMID: 23837797]
    BaF3 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity IL3 dependent human Ba/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity IL3 dependent human Ba/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 IC50
    26 1
    Compound: 15b, LDK378
    Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    HCC78 IC50
    0.058 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    		[PMID: 29174809]
    BaF3 IC50
    > 1000 1
    Compound: 3
    Antiproliferative activity against IL3-stimulated mouse BAF3 cells after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against IL3-stimulated mouse BAF3 cells after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    HCC78 IC50
    0.067 3
    Compound: Ceritinib
    Cytotoxicity against human HCC78 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    NCI-H3122 IC50
    27.2 1
    Compound: 16; LDK378
    Growth inhibition of human NCI-H3122 cells
    Growth inhibition of human NCI-H3122 cells
    		[PMID: 31005443]
    BaF3 IC50
    > 1000 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 G2032R mutant after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 G2032R mutant after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    Jurkat IC50
    2.918 3
    Compound: LDK378
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    HCT-116 IC50
    1.07 3
    Compound: 2
    Antiproliferative activity against ALK-negative human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against ALK-negative human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    BaF3 IC50
    > 2 3
    Compound: 6, LDK378
    Cytotoxicity against wild type mouse BA/F3 cells assessed as growth inhibition
    Cytotoxicity against wild type mouse BA/F3 cells assessed as growth inhibition
    		[PMID: 23837797]
    HCT-116 IC50
    1.82 3
    Compound: Ceritinib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 IC50
    33 1
    Compound: 2
    Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    KARPAS-299 IC50
    0.08 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    BaF3 IC50
    > 2000 1
    Compound: LDK378
    Antiproliferative activity against mouse BaF3 cells harboring CD74-ROS1 G2032R mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse BaF3 cells harboring CD74-ROS1 G2032R mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 25733882]
    HCT-116 IC50
    1.93 3
    Compound: LDK378
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    BaF3 IC50
    > 5 3
    Compound: Ceritinib
    Cytotoxicity against mouse BA/F3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BA/F3 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    KARPAS-299 IC50
    0.031 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    HEK-293T IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    KARPAS-299 IC50
    0.041 3
    Compound: Ceritinib
    Antiproliferative activity against human Karpas299 cells assessed as reduction in cell viability incubated for 4 hr by MTT assay
    Antiproliferative activity against human Karpas299 cells assessed as reduction in cell viability incubated for 4 hr by MTT assay
    		[PMID: 33069079]
    HeLa IC50
    0.94 3
    Compound: LDK378
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    KARPAS-299 IC50
    0.013 3
    Compound: LDK378
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    Hep 3B2 IC50
    2.16 3
    Compound: Ceritinib
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    HEp-2 IC50
    1.83 3
    Compound: LDK378
    Antiproliferative activity against human Hep2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Hep2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    KARPAS-299 IC50
    0.037 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    EA.hy 926 IC50
    1.01 3
    Compound: Ceritinib
    Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    Cytotoxicity against human EA.hy 926 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    		[PMID: 37087886]
    HepG2 IC50
    0.77 3
    Compound: LDK378
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    KARPAS-299 IC50
    0.047 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells by MTT assay
    Antiproliferative activity against human KARPAS-299 cells by MTT assay
    		[PMID: 36113668]
    HCC78 IC50
    0.018 3
    Compound: Ceritinib
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    HepG2 IC50
    4.08 3
    Compound: Ceritinib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    KARPAS-299 IC50
    0.026 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    		[PMID: 29174809]
    HCC78 IC50
    0.039 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    HK-2 IC50
    2.512 3
    Compound: Ceritinib
    Cytotoxicity against human HK-2 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    Cytotoxicity against human HK-2 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    		[PMID: 37087886]
    KARPAS-299 IC50
    0.041 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    		[PMID: 30223120]
    HCC78 IC50
    0.058 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    		[PMID: 29174809]
    KARPAS-299 IC50
    0.042 3
    Compound: Ceritinib
    Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    HT-29 IC50
    > 10 3
    Compound: Ceritinib
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    KARPAS-299 IC50
    0.027 3
    Compound: Ceritinib
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    HCC78 IC50
    0.058 3
    Compound: Ceritinib
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay
    		[PMID: 30223120]
    HT-29 IC50
    0.7 3
    Compound: LDK378
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    HCC78 IC50
    0.058 3
    Compound: LDK378
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    KARPAS-299 IC50
    0.02 3
    Compound: 2
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 assay
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 assay
    		[PMID: 35576654]
    HT-29 IC50
    1.03 3
    Compound: Ceritinib
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    KARPAS-299 IC50
    0.024 3
    Compound: LDK378
    Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    HCC78 IC50
    0.067 3
    Compound: Ceritinib
    Cytotoxicity against human HCC78 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCC78 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    HT-29 IC50
    1.12 3
    Compound: Ceritinib
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    HCC78 IC50
    226 1
    Compound: LDK378
    Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 25733882]
    KARPAS-299 IC50
    0.026 3
    Compound: LDK378
    Cytotoxicity against human KARPAS299 cells harboring NMP-ALK incubated for 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells harboring NMP-ALK incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    Jurkat IC50
    2.918 3
    Compound: LDK378
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    KARPAS-299 IC50
    0.027 3
    Compound: Ceritinib
    Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    HCC78 IC50
    506 1
    Compound: LDK378
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 fusion protein assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 fusion protein assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 25733882]
    KARPAS-299 IC50
    0.013 3
    Compound: LDK378
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    KARPAS-299 IC50
    0.02 3
    Compound: Ceritinib
    Cytotoxicity against human KARPAS299 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    HCC78 IC50
    > 1000 1
    Compound: 3
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    KARPAS-299 IC50
    0.02 3
    Compound: 2
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 assay
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 assay
    		[PMID: 35576654]
    NCI-H3122 CC50
    38 1
    Compound: LDK378
    Antiproliferative activity against wild type human NCI-H3122 cells
    Antiproliferative activity against wild type human NCI-H3122 cells
    		[PMID: 26235945]
    HCT-116 IC50
    1.07 3
    Compound: 2
    Antiproliferative activity against ALK-negative human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against ALK-negative human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    KARPAS-299 IC50
    0.02 3
    Compound: Ceritinib
    Cytotoxicity against human KARPAS299 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    BaF3 IC50
    40.7 1
    Compound: 6, LDK378
    Inhibition of ALK (unknown origin) transfected in mouse BA/F3 cells
    Inhibition of ALK (unknown origin) transfected in mouse BA/F3 cells
    		[PMID: 23837797]
    HCT-116 IC50
    1.82 3
    Compound: Ceritinib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    KARPAS-299 IC50
    0.024 3
    Compound: LDK378
    Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    BaF3 IC50
    41 1
    Compound: 2
    Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    HCT-116 IC50
    1.93 3
    Compound: LDK378
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    KARPAS-299 IC50
    0.026 3
    Compound: LDK378
    Cytotoxicity against human KARPAS299 cells harboring NMP-ALK incubated for 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells harboring NMP-ALK incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    KM12 IC50
    0.728 3
    Compound: Ceritinib
    Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    HEK-293T IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    KARPAS-299 IC50
    0.026 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    		[PMID: 29174809]
    HEp-2 IC50
    1.83 3
    Compound: LDK378
    Antiproliferative activity against human Hep2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Hep2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    KARPAS-299 IC50
    0.027 3
    Compound: Ceritinib
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    L02 IC50
    3.51 3
    Compound: Cer
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    HK-2 IC50
    2.512 3
    Compound: Ceritinib
    Cytotoxicity against human HK-2 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    Cytotoxicity against human HK-2 cells assessed as inhibition of cell growth measured after 48 to 72 hrs by MTT assay
    		[PMID: 37087886]
    KARPAS-299 IC50
    0.027 3
    Compound: Ceritinib
    Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    L02 IC50
    1.03 3
    Compound: Cer
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    HT-29 IC50
    0.7 3
    Compound: LDK378
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    KARPAS-299 IC50
    0.031 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    BaF3 IC50
    54.9 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    HT-29 IC50
    1.03 3
    Compound: Ceritinib
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    KARPAS-299 IC50
    0.037 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    BaF3 IC50
    57 1
    Compound: 2
    Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    HT-29 IC50
    1.12 3
    Compound: Ceritinib
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    KARPAS-299 IC50
    0.041 3
    Compound: Ceritinib
    Antiproliferative activity against human Karpas299 cells assessed as reduction in cell viability incubated for 4 hr by MTT assay
    Antiproliferative activity against human Karpas299 cells assessed as reduction in cell viability incubated for 4 hr by MTT assay
    		[PMID: 33069079]
    MCF7 IC50
    1.65 3
    Compound: Ceritinib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    HT-29 IC50
    > 10 3
    Compound: Ceritinib
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    MCF7 IC50
    >10 3
    Compound: Ceritinib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    KARPAS-299 IC50
    0.041 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    		[PMID: 30223120]
    HeLa IC50
    0.94 3
    Compound: LDK378
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    KARPAS-299 IC50
    0.042 3
    Compound: Ceritinib
    Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    MCF7 IC50
    1.754 3
    Compound: LDK378
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    Hep 3B2 IC50
    2.16 3
    Compound: Ceritinib
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    KARPAS-299 IC50
    0.047 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells by MTT assay
    Antiproliferative activity against human KARPAS-299 cells by MTT assay
    		[PMID: 36113668]
    MCF7 IC50
    1.87 3
    Compound: LDK378
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    BaF3 IC50
    64 1
    Compound: 2
    Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    HepG2 IC50
    0.77 3
    Compound: LDK378
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    KARPAS-299 IC50
    0.08 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    HepG2 IC50
    4.08 3
    Compound: Ceritinib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    MDA-MB-231 IC50
    2.71 3
    Compound: Ceritinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    KARPAS-299 IC50
    22.8 1
    Compound: 15b, LDK378
    Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay
    Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    KARPAS-299 IC50
    84 1
    Compound: 3
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    MDA-MB-231 IC50
    1.82 3
    Compound: Ceritinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    Jurkat IC50
    2.918 3
    Compound: LDK378
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    Kelly EC50
    142 1
    Compound: 2
    Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    BaF3 CC50
    75 1
    Compound: LDK378
    Antiproliferative activity against mouse BAF3 cells expressing ALK L1196M mutant
    Antiproliferative activity against mouse BAF3 cells expressing ALK L1196M mutant
    		[PMID: 26235945]
    BaF3 CC50
    75 1
    Compound: LDK378
    Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay
    Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay
    		[PMID: 26923695]
    KARPAS-299 IC50
    0.013 3
    Compound: LDK378
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    KM12 IC50
    0.728 3
    Compound: Ceritinib
    Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    KARPAS-299 IC50
    0.02 3
    Compound: 2
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 assay
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 assay
    		[PMID: 35576654]
    MDA-MB-468 IC50
    2.708 3
    Compound: LDK378
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    MCF7 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    KARPAS-299 IC50
    0.02 3
    Compound: Ceritinib
    Cytotoxicity against human KARPAS299 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    KARPAS-299 IC50
    84 1
    Compound: 3
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    MCF7 IC50
    1.65 3
    Compound: Ceritinib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H3122 IC50
    96 1
    Compound: 3
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    KARPAS-299 IC50
    0.024 3
    Compound: LDK378
    Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    MCF7 IC50
    1.754 3
    Compound: LDK378
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H2228 IC50
    97 1
    Compound: 16; LDK378
    Growth inhibition of human NCI-H2228 cells
    Growth inhibition of human NCI-H2228 cells
    		[PMID: 31005443]
    KARPAS-299 IC50
    0.026 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    		[PMID: 29174809]
    MCF7 IC50
    1.87 3
    Compound: LDK378
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    KARPAS-299 IC50
    0.026 3
    Compound: LDK378
    Cytotoxicity against human KARPAS299 cells harboring NMP-ALK incubated for 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells harboring NMP-ALK incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    MDA-MB-231 IC50
    1.82 3
    Compound: Ceritinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    BaF3 IC50
    101 1
    Compound: 2
    Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    KARPAS-299 IC50
    0.027 3
    Compound: Ceritinib
    Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    MDA-MB-231 IC50
    2.71 3
    Compound: Ceritinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H2228 IC50
    102.6 1
    Compound: Ceritinib
    Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay
    Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 25644671]
    KARPAS-299 IC50
    0.027 3
    Compound: Ceritinib
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    MDA-MB-468 IC50
    2.708 3
    Compound: LDK378
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    SU-DHL-1 IC50
    122 1
    Compound: 3
    Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    KARPAS-299 IC50
    0.031 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    NCI-H1299 IC50
    2.92 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    Kelly EC50
    142 1
    Compound: 2
    Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    KARPAS-299 IC50
    0.037 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    NCI-H1581 IC50
    2.18 3
    Compound: Ceritinib
    Antiproliferative activity against human NC-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NC-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 IC50
    164 1
    Compound: 2
    Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    KARPAS-299 IC50
    0.041 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay
    		[PMID: 30223120]
    NCI-H1581 IC50
    2.31 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    SH-SY5Y EC50
    186 1
    Compound: 2
    Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    KARPAS-299 IC50
    0.041 3
    Compound: Ceritinib
    Antiproliferative activity against human Karpas299 cells assessed as reduction in cell viability incubated for 4 hr by MTT assay
    Antiproliferative activity against human Karpas299 cells assessed as reduction in cell viability incubated for 4 hr by MTT assay
    		[PMID: 33069079]
    NCI-H1975 IC50
    > 10 3
    Compound: LDK378
    Cytotoxicity against EGFR-positive human H1975 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against EGFR-positive human H1975 cells incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    NCI-H1299 IC50
    1.74 3
    Compound: Cer
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    KARPAS-299 IC50
    0.042 3
    Compound: Ceritinib
    Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    NCI-H2228 CC50
    0.025 3
    Compound: LDK378
    Cytotoxicity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 26712094]
    NCI-H1299 IC50
    1.62 3
    Compound: Cer
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    KARPAS-299 IC50
    0.047 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells by MTT assay
    Antiproliferative activity against human KARPAS-299 cells by MTT assay
    		[PMID: 36113668]
    NCI-H1299 IC50
    2.92 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    NCI-H2228 IC50
    0.026 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    		[PMID: 30223120]
    KARPAS-299 IC50
    0.08 3
    Compound: Ceritinib
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    NCI-H2228 IC50
    0.03 3
    Compound: 2
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    NCI-H1581 IC50
    2.18 3
    Compound: Ceritinib
    Antiproliferative activity against human NC-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NC-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    KARPAS-299 IC50
    22.8 1
    Compound: 15b, LDK378
    Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay
    Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    NCI-H1581 IC50
    2.31 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H2228 IC50
    0.045 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    KARPAS-299 IC50
    22.8 1
    Compound: 6, LDK378
    Cytotoxicity against human KARPAS299 cells expressing NPM-ALK fusion gene assessed as growth inhibition
    Cytotoxicity against human KARPAS299 cells expressing NPM-ALK fusion gene assessed as growth inhibition
    		[PMID: 23837797]
    NCI-H2228 IC50
    0.066 3
    Compound: LDK378
    Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H1975 IC50
    >10 3
    Compound: LDK378
    Cytotoxicity against EGFR-positive human H1975 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against EGFR-positive human H1975 cells incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    NCI-H2228 CC50
    0.025 3
    Compound: LDK378
    Cytotoxicity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 26712094]
    KARPAS-299 IC50
    84 1
    Compound: 3
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    NCI-H2228 IC50
    0.079 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H2228 IC50
    0.104 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    NCI-H2228 IC50
    0.099 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    		[PMID: 29174809]
    NCI-H2228 IC50
    0.104 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    NCI-H2228 IC50
    0.079 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H2228 IC50
    0.107 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    NCI-H2228 IC50
    0.03 3
    Compound: 2
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    NCI-H2228 IC50
    0.15 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    NCI-H2228 IC50
    0.066 3
    Compound: LDK378
    Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H2228 IC50
    1.07 3
    Compound: Ceritinib
    Antiproliferative activity against human H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33069079]
    NCI-H2228 IC50
    0.15 3
    Compound: Ceritinib
    Cytotoxicity against human NCI-H2228 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human NCI-H2228 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    NCI-H2228 IC50
    0.58 3
    Compound: Cer
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H2228 IC50
    0.162 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells by MTT assay
    Antiproliferative activity against human NCI-H2228 cells by MTT assay
    		[PMID: 36113668]
    KM12 IC50
    0.728 3
    Compound: Ceritinib
    Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    NCI-H2228 IC50
    1.07 3
    Compound: Ceritinib
    Antiproliferative activity against human H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33069079]
    NCI-H2228 IC50
    0.59 3
    Compound: Cer
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    Kelly EC50
    142 1
    Compound: 2
    Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    NCI-H2228 IC50
    1.3 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    NCI-H2228 IC50
    0.15 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    L02 IC50
    1.03 3
    Compound: Cer
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H2228 IC50
    0.107 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    NCI-H2228 IC50
    1.98 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4/ALK L1196M mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4/ALK L1196M mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    L02 IC50
    3.51 3
    Compound: Cer
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H2228 IC50
    102.6 1
    Compound: Ceritinib
    Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay
    Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 25644671]
    NCI-H2228 IC50
    0.045 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    NCI-H2228 IC50
    1.3 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    MCF7 IC50
    1.65 3
    Compound: Ceritinib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H2228 IC50
    15 1
    Compound: 2
    Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay
    Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay
    		[PMID: 29627725]
    MCF7 IC50
    1.754 3
    Compound: LDK378
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H2228 IC50
    2.9 3
    Compound: LDK378
    Cytotoxicity in human NCI-H2228 cells harboring EML4-fused ALK variant 3 incubated for 72 hrs by alamar blue reagent based assay
    Cytotoxicity in human NCI-H2228 cells harboring EML4-fused ALK variant 3 incubated for 72 hrs by alamar blue reagent based assay
    		[PMID: 31425908]
    NCI-H2228 IC50
    0.162 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells by MTT assay
    Antiproliferative activity against human NCI-H2228 cells by MTT assay
    		[PMID: 36113668]
    MCF7 IC50
    1.87 3
    Compound: LDK378
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H2228 IC50
    22.1 1
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell proliferation measured by CCK8 assay
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell proliferation measured by CCK8 assay
    		[PMID: 34245852]
    NCI-H2228 IC50
    1.98 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4/ALK L1196M mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4/ALK L1196M mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    MCF7 IC50
    > 10 3
    Compound: Ceritinib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    NCI-H3122 IC50
    0.018 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H2228 IC50
    0.026 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    		[PMID: 30223120]
    NCI-H3122 CC50
    0.038 3
    Compound: LDK378
    Cytotoxicity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 26712094]
    NCI-H2228 IC50
    0.099 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    		[PMID: 29174809]
    NCI-H3122 IC50
    0.043 3
    Compound: LDK378
    Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H2228 IC50
    0.15 3
    Compound: Ceritinib
    Cytotoxicity against human NCI-H2228 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human NCI-H2228 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    NCI-H3122 IC50
    0.043 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK positive human NC-H3122 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NC-H3122 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H2228 IC50
    2.9 3
    Compound: LDK378
    Cytotoxicity in human NCI-H2228 cells harboring EML4-fused ALK variant 3 incubated for 72 hrs by alamar blue reagent based assay
    Cytotoxicity in human NCI-H2228 cells harboring EML4-fused ALK variant 3 incubated for 72 hrs by alamar blue reagent based assay
    		[PMID: 31425908]
    NCI-H3122 IC50
    1.1 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33471528]
    BaF3 IC50
    234 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    NCI-H3122 CC50
    0.038 3
    Compound: LDK378
    Cytotoxicity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 26712094]
    MDA-MB-231 IC50
    1.82 3
    Compound: Ceritinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    NCI-H3122 IC50
    1.1 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    MDA-MB-231 IC50
    2.71 3
    Compound: Ceritinib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H3122 EC50
    15 1
    Compound: 2
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    NCI-H3122 IC50
    0.043 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK positive human NC-H3122 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NC-H3122 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H3122 IC50
    0.043 3
    Compound: LDK378
    Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    MDA-MB-468 IC50
    2.708 3
    Compound: LDK378
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H3122 IC50
    96 1
    Compound: 3
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    NCI-H3122 IC50
    0.06 3
    Compound: Cer
    Antiproliferative activity against human NCI-H3122 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H1299 IC50
    1.62 3
    Compound: Cer
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H460 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 29174809]
    NCI-H1299 IC50
    1.74 3
    Compound: Cer
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H460 IC50
    > 10 3
    Compound: Ceritinib
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    NCI-H3122 IC50
    0.018 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H3122 IC50
    1.1 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33471528]
    NCI-H460 IC50
    10.32 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H1299 IC50
    2.92 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    NCI-H1581 IC50
    2.18 3
    Compound: Ceritinib
    Antiproliferative activity against human NC-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NC-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    PC-3 IC50
    0.76 3
    Compound: LDK378
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H3122 IC50
    1.1 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    NCI-H460 IC50
    >1 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 29174809]
    NCI-H1581 IC50
    2.31 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    PC-3 IC50
    0.941 3
    Compound: Ceritinib
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    PC-3 IC50
    1.02 3
    Compound: LDK378
    Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H1975 IC50
    > 10 3
    Compound: LDK378
    Cytotoxicity against EGFR-positive human H1975 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against EGFR-positive human H1975 cells incubated for 72 hrs by MTT assay
    		[PMID: 33069075]
    NCI-H460 IC50
    10.32 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    Raji IC50
    0.49 3
    Compound: LDK378
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H460 IC50
    >10 3
    Compound: Ceritinib
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    SK-N-SH EC50
    303 1
    Compound: 2
    Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    SH-SY5Y IC50
    0.37 3
    Compound: Ceritinib
    Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    SH-SY5Y EC50
    186 1
    Compound: 2
    Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    BaF3 IC50
    319.5 1
    Compound: 15b, LDK378
    Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    SK-N-AS EC50
    1045 1
    Compound: 2
    Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    BaF3 IC50
    320 1
    Compound: 6, LDK378
    Cytotoxicity against mouse BA/F3 cells transfected with Tel-InsR gene assessed as growth inhibition
    Cytotoxicity against mouse BA/F3 cells transfected with Tel-InsR gene assessed as growth inhibition
    		[PMID: 23837797]
    SK-N-FI EC50
    349 1
    Compound: 2
    Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    SK-N-FI EC50
    349 1
    Compound: 2
    Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    BaF3 IC50
    444 1
    Compound: 2
    Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    SK-N-SH EC50
    303 1
    Compound: 2
    Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    PC-3 IC50
    0.941 3
    Compound: Ceritinib
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H2228 CC50
    0.025 3
    Compound: LDK378
    Cytotoxicity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 26712094]
    SU-DHL-1 IC50
    122 1
    Compound: 3
    Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    NCI-H2228 IC50
    0.026 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    		[PMID: 30223120]
    SU-DHL-1 IC50
    15 1
    Compound: 2
    Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay
    Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay
    		[PMID: 29627725]
    PC-3 IC50
    0.76 3
    Compound: LDK378
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    PC-3 IC50
    1.02 3
    Compound: LDK378
    Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H2228 IC50
    0.03 3
    Compound: 2
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    		[PMID: 35576654]
    U2OS IC50
    0.85 3
    Compound: LDK378
    Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H2228 IC50
    0.045 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31492532]
    Vero IC50
    2.86 3
    Compound: LDK378
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    		10.1101/2020.03.20.999730
    BaF3 IC50
    576.6 1
    Compound: 19
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 33243531]
    Raji IC50
    0.49 3
    Compound: LDK378
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H2228 IC50
    0.066 3
    Compound: LDK378
    Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    Vero CC50
    6.84 3
    Compound: LDK378
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    		10.1101/2020.03.20.999730
    NCI-H2228 IC50
    0.079 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    BaF3 IC50
    668 1
    Compound: 2
    Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    NCI-H2228 IC50
    0.099 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay
    		[PMID: 29174809]
    BaF3 IC50
    726 1
    Compound: 3
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    NCI-H2228 IC50
    0.104 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34534734]
    BaF3 IC50
    780.5 1
    Compound: 19
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 33243531]
    A549 GI50
    845 1
    Compound: 1
    Cytotoxicity against ALK-negative human A549 cells harboring wild type PI3KCA and CDKN2A and KRAS mutations assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against ALK-negative human A549 cells harboring wild type PI3KCA and CDKN2A and KRAS mutations assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32184963]
    NCI-H2228 IC50
    0.107 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    		[PMID: 33756437]
    NCI-H2228 IC50
    0.15 3
    Compound: Ceritinib
    Cytotoxicity against human NCI-H2228 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human NCI-H2228 cells incubated for 72 hrs by MTT assay
    		[PMID: 30927566]
    SK-N-AS EC50
    1045 1
    Compound: 2
    Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    NCI-H2228 IC50
    0.15 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33581554]
    SH-SY5Y IC50
    0.37 3
    Compound: Ceritinib
    Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    NCI-H2228 IC50
    0.162 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells by MTT assay
    Antiproliferative activity against human NCI-H2228 cells by MTT assay
    		[PMID: 36113668]
    BaF3 IC50
    2477 1
    Compound: 2; LDK378
    Antiproliferative activity against wild type mouse BaF3 cells assessed as reduction in cell growth incubated for 2 to 3 days by Bright-Glo luciferase assay
    Antiproliferative activity against wild type mouse BaF3 cells assessed as reduction in cell growth incubated for 2 to 3 days by Bright-Glo luciferase assay
    		[PMID: 26750252]
    BaF3 IC50
    2477 1
    Compound: 15b, LDK378
    Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay
    		[PMID: 23742252]
    NCI-H2228 IC50
    0.58 3
    Compound: Cer
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    BaF3 EC50
    2500 1
    Compound: Ceritinib
    Inhibition of EGFR T790M/L858R double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR T790M/L858R double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    NCI-H2228 IC50
    0.59 3
    Compound: Cer
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H2228 IC50
    1.07 3
    Compound: Ceritinib
    Antiproliferative activity against human H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33069079]
    BaF3 EC50
    2660 1
    Compound: Ceritinib
    Inhibition of EGFR T790M exon19 deletion double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Inhibition of EGFR T790M exon19 deletion double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 28528303]
    BaF3 IC50
    2747 1
    Compound: 2
    Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    NCI-H2228 IC50
    1.3 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    BaF3 IC50
    5512 1
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay
    Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 26568289]
    NCI-H2228 IC50
    1.98 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells harboring EML4/ALK L1196M mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H2228 cells harboring EML4/ALK L1196M mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    NCI-H2228 IC50
    102.6 1
    Compound: Ceritinib
    Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay
    Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay
    		[PMID: 25644671]
    U2OS IC50
    0.85 3
    Compound: LDK378
    Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H2228 IC50
    15 1
    Compound: 2
    Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay
    Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay
    		[PMID: 29627725]
    Vero CC50
    6.84 3
    Compound: LDK378
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    		10.1101/2020.03.20.999730
    Vero IC50
    2.86 3
    Compound: LDK378
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    		10.1101/2020.03.20.999730
    NCI-H2228 IC50
    2.9 3
    Compound: LDK378
    Cytotoxicity in human NCI-H2228 cells harboring EML4-fused ALK variant 3 incubated for 72 hrs by alamar blue reagent based assay
    Cytotoxicity in human NCI-H2228 cells harboring EML4-fused ALK variant 3 incubated for 72 hrs by alamar blue reagent based assay
    		[PMID: 31425908]
    NCI-H2228 IC50
    22.1 1
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell proliferation measured by CCK8 assay
    Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell proliferation measured by CCK8 assay
    		[PMID: 34245852]
    NCI-H2228 IC50
    97 1
    Compound: 16; LDK378
    Growth inhibition of human NCI-H2228 cells
    Growth inhibition of human NCI-H2228 cells
    		[PMID: 31005443]
    NCI-H3122 CC50
    0.038 3
    Compound: LDK378
    Cytotoxicity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 26712094]
    NCI-H3122 CC50
    38 1
    Compound: LDK378
    Antiproliferative activity against wild type human NCI-H3122 cells
    Antiproliferative activity against wild type human NCI-H3122 cells
    		[PMID: 26235945]
    NCI-H3122 EC50
    15 1
    Compound: 2
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    NCI-H3122 IC50
    0.018 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    NCI-H3122 IC50
    0.043 3
    Compound: Ceritinib
    Antiproliferative activity against EML4-ALK positive human NC-H3122 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against EML4-ALK positive human NC-H3122 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    NCI-H3122 IC50
    0.043 3
    Compound: LDK378
    Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H3122 IC50
    0.06 3
    Compound: Cer
    Antiproliferative activity against human NCI-H3122 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as inhibition of cell growth incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H3122 IC50
    0.06 3
    Compound: Cer
    Antiproliferative activity against human NCI-H3122 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as inhibition of cell growth pretreated with GSH followed by compound addition and incubated for 3 to 5 days by MTT assay
    		[PMID: 36628851]
    NCI-H3122 IC50
    1.1 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33471528]
    NCI-H3122 IC50
    1.1 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 33453602]
    NCI-H3122 IC50
    27.2 1
    Compound: 16; LDK378
    Growth inhibition of human NCI-H3122 cells
    Growth inhibition of human NCI-H3122 cells
    		[PMID: 31005443]
    NCI-H3122 IC50
    96 1
    Compound: 3
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    NCI-H460 IC50
    10.32 3
    Compound: LDK378
    Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    NCI-H460 IC50
    > 1 3
    Compound: Ceritinib
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 29174809]
    NCI-H460 IC50
    > 10 3
    Compound: Ceritinib
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay
    		[PMID: 27474925]
    PC-3 IC50
    0.76 3
    Compound: LDK378
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    PC-3 IC50
    0.941 3
    Compound: Ceritinib
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35691173]
    PC-3 IC50
    1.02 3
    Compound: LDK378
    Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay
    Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay
    		[PMID: 35939995]
    Raji IC50
    0.49 3
    Compound: LDK378
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    SH-SY5Y EC50
    186 1
    Compound: 2
    Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    SH-SY5Y IC50
    0.37 3
    Compound: Ceritinib
    Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay
    		[PMID: 34237620]
    SK-N-AS EC50
    1045 1
    Compound: 2
    Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    SK-N-FI EC50
    349 1
    Compound: 2
    Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    SK-N-SH EC50
    303 1
    Compound: 2
    Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay
    		[PMID: 26568289]
    SR IC50
    2.2 1
    Compound: Ceritinib
    Antiproliferative activity against ALK positive human SR cells
    Antiproliferative activity against ALK positive human SR cells
    		[PMID: 33751979]
    SU-DHL-1 IC50
    122 1
    Compound: 3
    Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay
    		[PMID: 29288940]
    SU-DHL-1 IC50
    15 1
    Compound: 2
    Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay
    Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay
    		[PMID: 29627725]
    U2OS IC50
    0.85 3
    Compound: LDK378
    Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    		[PMID: 31177074]
    Vero CC50
    6.84 3
    Compound: LDK378
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    		10.1101/2020.03.20.999730
    Vero IC50
    2.86 3
    Compound: LDK378
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    		10.1101/2020.03.20.999730
    In Vitro

    Ceritinib also inhibits RET (IC50=400 nM), FGFR3 (IC50=430 nM), LCK (IC50=560 nM), JAK2 (IC50=610 nM), Aurora (IC50=660 nM), LYN (50=840 nM), EGFR (IC50=900 nM), and FGFR4 (IC50=950 nM)[1].
    Ceritinib retains high potency against the ALK enzymatic activity with an IC50 value of 200 pM and shows only strong inhibition against IGF-1R, InsR, and STK22D out of a panel of 46 kinases with a minimum selectivity of 70-fold. In Ba/F3 cells transfected with various kinases, Ceritinib inhibits ALK activity with an IC50 value of 40.7 nM and had IC50 values of >100 nM against all other kinases tested. Ceritinib (LDK378) shows potent antiproliferative activity with an IC50 value of 22.8 nM in Karpas 299 human non-Hodgkin’s Ki-positive large cell lymphoma carrying the NPM-ALK fusion gene and 26 nM in Ba/F3 cells transfected with the NPM-ALK fusion gene. Ceritinib also shows good selectivity over wild-type Ba/F3 cells (IC50>2 μM) and Ba/F3 cells transfected with Tel-InsR gene (IC50=320 nM)[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ceritinib Related Antibodies
    In Vivo

    Ceritinib has an excellent pharmacokinetics profile in rodents and non-rodents with an oral bioavailability of >50%. Ceritinib demonstrates dose-dependent tumor growth inhibition and achieved partial tumor regression in the Karpas 299 rat xenograft model with daily administration but is capable of achieving complete tumor regression in the H2228 NSCLC rat xenograft model, which carries the EML4-ALK fusion gene. In both models, Ceritinib is well tolerated in animals. Ceritinib is further assessed for its ADME profile and is found to have a relatively good metabolic stability in liver microsomes, modest CYP3A4 inhibition, some hERG inhibition with an IC50 value of 46 μM in hERG patch clamp experiments, but no evidence of QTc prolongation in both dog and monkey telemetry studies[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    558.14

    Formula

    C28H36ClN5O3S
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(C(C)C)=O)=N3
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 12.5 mg/mL (22.40 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7917 mL 8.9583 mL 17.9167 mL
    5 mM 0.3583 mL 1.7917 mL 3.5833 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 0.5 mg/mL (0.90 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 0.5 mg/mL (0.90 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.95%

    SDS (393 KB)

    COA (249 KB) HNMR (137 KB) RP-HPLC (86 KB) MS (69 KB)

    Handling Instructions (2659 KB)
    References
    Animal Administration
    [1]

    In vivo PK studies are conducted in mice, rats, dogs, and cynomolgus monkeys. Ceritinib (LDK378) (HCl salt) is administered to male Balb/c mice intravenously via tail vein at 5 mg/kg (n=3) and orally via gavage at 20 mg/kg (n=3). By use of the same formulation, Ceritinib (LDK378) (HCl salt) is dosed to Sprague-Dawley rats intravenously via the tail vein at 3 mg/kg (n=3) and orally via gavage at 10 mg/kg (n=3). Blood samples are collected serially at scheduled times over 24 h after dosing. Male beagle dogs receive a single intravenous (n=2) or oral (n=3) dose of Ceritinib (phosphate salt) as an intravenous solution at 5 mg/kg and an oral suspension at 20 mg/kg, respectively. Male cynomologus monkeys receive single intravenous (n=2) or oral (n=3) dose of Ceritinib (free base) as an intravenous solution at 5 mg/kg and an oral suspension at 60 mg/kg, respectively. Blood samples for plasma are collected at prescheduled times over 144 h after dosing[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7917 mL 8.9583 mL 17.9167 mL 44.7916 mL
    5 mM 0.3583 mL 1.7917 mL 3.5833 mL 8.9583 mL
    10 mM 0.1792 mL 0.8958 mL 1.7917 mL 4.4792 mL
    15 mM 0.1194 mL 0.5972 mL 1.1944 mL 2.9861 mL
    20 mM 0.0896 mL 0.4479 mL 0.8958 mL 2.2396 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ceritinib Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ceritinib1032900-25-6LDK378LDK 378LDK-378Anaplastic lymphoma kinase (ALK)Insulin ReceptorIGF-1RAnaplastic lymphoma kinaseALK tyrosine kinase receptorCD246Cluster of differentiation 246Insulin-like growth factor-1 receptorInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ceritinib
    Cat. No.:
    HY-15656
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.